Inzomelid declares positive CAPS treatment results, completes Phase I
Category: #health  By Pankaj Singh  Date: 2020-03-28
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Inzomelid declares positive CAPS treatment results, completes Phase I

Inflammasome biotech company Inflazome has reportedly announced the successful completion of Inzomelid’s Phase I clinical study. In addition, the firm has also declared that it has observed positive results from a CAPS (Cryopyrin-Associated Periodic Syndrome) patient who was successfully does with Inzomelid. The results will now support Inzomelid’s progression into Phase II clinical trials.

For the uninitiated, CAPS is an autoinflammatory orphan disease caused due to the mutated NLRP3. Activation of this NLRP3 inflammasome is implicated in numerous diseases that occur due to chronic, harmful inflammation. Inzomelid is basically an orally available, selective small molecule inhibitor of the NLRP3 inflammasome.

The preliminary analysis derived from the CAPS part of this clinical study depicted that a patient having a confirmed NLRP3 mutation and suffering from a CAPS-related flare exhibited appreciable clinical improvement merely within a few hours and was also in remission within days. The company, as per reports, is planning to conduct a Phase II trial in order to identify how much the best dose for patients suffering from CAPS should be.

Dr. Thomas Jung, Chief Medical Officer, Inflazome, has been quoted to state that that the positive results obtained from the Phase I trials of the firm’s lead candidates, Inzomelid and Somalix, go on to further validate its technology platform as Inflazome heads toward numerous Phase II trials later this year. The company believes that the Inzomelid CAPS data is the first example of positive data within a human disease setting having a small-molecule NLRP3 inhibitor, Jung added. He also claimed that the firm aims to develop drugs that have a high unmet medical need exists, and Inzomelid clearly fits the bill in this case.

For the record, Somalix, the other NLRP3 inflammasome inhibitor of Inflazome, has also successfully completed Phase I trials. It is a peripherally-restricted, an orally available drug fused or inflammatory diseases, has brilliant safety and tolerability in healthy subjects, and is anticipated to enter Phase II clinical trials in 2020.

Source Credits: https://inflazome.com/news/46



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Matterport announces partnership with Apex to digitize built world

Matterport announces partnership with Apex to digitize built world

By Pankaj Singh

Matterport, Inc., a 3D media platform developer, has recently announced a partnership with Apex, a consulting, engineering, and field services firm. This partnership deal has been entered with an objective to allow ret...

Stop & Shop collaborates with Volta Charging to offer EV charging

Stop & Shop collaborates with Volta Charging to offer EV charging

By Pankaj Singh

Stop & Shop has reportedly partnered with Volta Industries Inc. to install five electric vehicle charging stations across its Northeast stores fleet.

These stations will enable ...

CPSI announces a licensing partnership with Medicomp Systems

CPSI announces a licensing partnership with Medicomp Systems

By Pankaj Singh

CPSI Inc., a healthcare solution provider, has reportedly announced a licensing partnership with Medicomp Systems, a company that produces solutions for relevant, actionable, and usable medical data.